FDA
-
-
-
-
-
-
-
PTC Therapeutics withdraws Translarna drug application after FDA feedback
-
-
-
-
-
-
-
Truist: 'QURE Update Minimal Read-Through To PTCT & WVE, In Our View'
-
-
-
-
-
-
-
PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
-
-
-
-
-
-
-
Sephience™ (sepiapterin) Granted Marketing Authorization by the European Commission for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
-
-
-
-
-
-
-
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
-
-
-
-
-
-
-
RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
-
-
-
-
-
-
-
JPMorgan Reiterates Overweight Rating on PTC Therapeutics (PTCT)
-
328,282 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

